AsiaStrategy H1 net loss widens 15% to $648,698; revenue rises 40% to $6.12 million
Bitget2026/10/06 20:11AsiaStrategy posted a net loss of $648,698 for the six months ended June 30, 2026, widening from $563,147 a year earlier. Revenue rose 40% to $6.12 million, while loss from operations widened to $978,154. Unrealized losses on digital assets were $867,554, and unrealized gains on investment in equity securities were $1.26 million. Total assets fell to $36.99 million, while cash and cash equivalents slipped to $1.31 million. The group said it held digital assets valued at $2.21 million at June 30, including $1.76 million of restricted Bitcoin pledged as collateral. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AsiaStrategy published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-107204), on October 06, 2026, and is solely responsible for the information contained therein.
- AsiaStrategy posted a net loss of $648,698 for the six months ended June 30, 2026, widening from $563,147 a year earlier.
- Revenue rose 40% to $6.12 million, while loss from operations widened to $978,154.
- Unrealized losses on digital assets were $867,554, and unrealized gains on investment in equity securities were $1.26 million.
- Total assets fell to $36.99 million, while cash and cash equivalents slipped to $1.31 million.
- The group said it held digital assets valued at $2.21 million at June 30, including $1.76 million of restricted Bitcoin pledged as collateral.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
